1 |
Lam DK, Sandor GK, Holmes HI, Evans AW, Clokie CM. A review of bisphosphonate-associated osteonecrosis of the jaws and its management. J Can Dent Assoc 2007;73:417-22.
|
2 |
Yarom N, Yahalom R, Shoshani Y, Hamed W, Regev E, Elad S. Osteonecrosis of the jaw induced by orally administered bisphosphonates: incidence, clinical features, predisposing factors and treatment outcome. Osteoporos Int 2007;18:1363-70.
DOI
ScienceOn
|
3 |
Phal PM, Myall RW, Assael LA, Weissman JL. Imaging findings of bisphosphonate-associated osteonecrosis of the jaws. AJNR Am J Neuroradiol 2007;28:1139-45.
DOI
ScienceOn
|
4 |
Bisdas S, Chambron Pinho N, Smolarz A, Sader R, Vogl TJ, Mack MG. Biphosphonate-induced osteonecrosis of the jaws: CT and MRI spectrum of findings in 32 patients. Clin Radiol 2008; 63:71-7.
DOI
ScienceOn
|
5 |
Hansen T, Kunkel M, Springer E, Walter C, Weber A, Siegel E, et al. Actinomycosis of the jaws-histopathological study of 45 patients shows significant involvement in bisphosphonate-associated osteonecrosis and infected osteoradionecrosis. Virchows Arch 2007;451:1009-17.
DOI
ScienceOn
|
6 |
Marx RE, Cillo JE Jr, Ulloa JJ. Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment. J Oral Maxillofac Surg 2007;65: 2397-410.
DOI
ScienceOn
|
7 |
Rosen HN, Moses AC, Garber J, Iloputaife ID, Ross DS, Lee SL, et al. Serum CTX: a new marker of bone resorption that shows treatment effect more often than other markers because of low coefficient of variability and large changes with bisphosphonate therapy. Calcif Tissue Int 2000;66:100-3.
DOI
ScienceOn
|
8 |
Bize R, Lamy O, Peytremann-Bridevaux I. Osteoporotic fracture in menopausal women: alendronate reduces the risk. Rev Med Suisse 2008;4:2703.
|
9 |
Advisory Task Force on Bisphosphonate-Related Ostenonecrosis of the Jaws, American Association of Oral and Maxillofacial Surgeons. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg 2007;65:369-76.
DOI
ScienceOn
|
10 |
Bedogni A, Blandamura S, Lokmic Z, Palumbo C, Ragazzo M, Ferrari F, et al. Bisphosphonate-associated jawbone osteonecrosis: a correlation between imaging techniques and histopathology. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2008;105:358-64.
DOI
ScienceOn
|
11 |
Green JR. Bisphosphonates: preclinical review. Oncologist 2004;9 Suppl 4:3-13.
DOI
|
12 |
Mavrokokki T, Cheng A, Stein B, Goss A. Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia. J Oral Maxillofac Surg 2007;65:415-23.
DOI
ScienceOn
|
13 |
McClung MR. Bisphosphonates. Endocrinol Metab Clin North Am 2003;32:253-71.
DOI
ScienceOn
|
14 |
Lehenkari PP, Kellinsalmi M, Napankangas JP, Ylitalo KV, Monkkonen J, Rogers MJ, et al. Further insight into mechanism of action of clodronate: inhibition of mitochondrial ADP/ATP translocase by a nonhydrolyzable, adenine-containing metabolite. Mol Pharmacol 2002;61:1255-62.
DOI
ScienceOn
|
15 |
Alakangas A, Selander K, Mulari M, Halleen J, Lehenkari P, Monkkonen J, et al. Alendronate disturbs vesicular trafficking in osteoclasts. Calcif Tissue Int 2002;70:40-7.
DOI
ScienceOn
|
16 |
Sawatari Y, Marx RE. Bisphosphonates and bisphosphonate induced osteonecrosis. Oral Maxillofac Surg Clin North Am 2007; 19:487-98, v-vi.
DOI
ScienceOn
|
17 |
Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, et al.; HORIZON Pivotal Fracture Trial. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007;356:1809-22.
DOI
ScienceOn
|
18 |
Marx RE, Sawatari Y, Fortin M, Broumand V. Bisphosphonateinduced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg. 2005;63:1567-75.
DOI
ScienceOn
|
19 |
Reid IR, Bolland MJ, Grey AB. Is bisphosphonate-associated osteonecrosis of the jaw caused by soft tissue toxicity? Bone 2007; 41:318-20.
DOI
ScienceOn
|
20 |
Badros A, Weikel D, Salama A, Goloubeva O, Schneider A, Rapoport A, et al. Osteonecrosis of the jaw in multiple myeloma patients: clinical features and risk factors. J Clin Oncol 2006;24:945-52.
DOI
ScienceOn
|
21 |
Epstein S. Update of current therapeutic options for the treatment of postmenopausal osteoporosis. Clin Ther 2006;28:151-73.
DOI
ScienceOn
|
22 |
Saad F, Lipton A. Clinical benefits and considerations of bisphosphonate treatment in metastatic bone disease. Semin Oncol 2007;34(6 Suppl 4):S17-23.
|
23 |
Owens G, Jackson R, Lewiecki EM. An integrated approach: bisphosphonate management for the treatment of osteoporosis. Am J Manag Care 2007;13 Suppl 11:S290-308; quiz S309-12.
|
24 |
Migliorati CA, Casiglia J, Epstein J, Jacobsen PL, Siegel MA, Woo SB. Managing the care of patients with bisphosphonate-associated osteonecrosis: an American Academy of Oral Medicine position paper. J Am Dent Assoc 2005;136:1658-68.
DOI
|
25 |
Woo SB, Hellstein JW, Kalmar JR. Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med 2006;144:753-61.
DOI
ScienceOn
|
26 |
Brooks JK, Gilson AJ, Sindler AJ, Ashman SG, Schwartz KG, Nikitakis NG. Osteonecrosis of the jaws associated with use of risedronate: report of 2 new cases. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2007;103:780-6.
DOI
ScienceOn
|
27 |
Khosla S, Burr D, Cauley J, Dempster DW, Ebeling PR, Felsenberg D, et al. American Society for Bone and Mineral Research. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2007;22:1479-91.
DOI
ScienceOn
|
28 |
Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 2003;61:1115-7.
DOI
ScienceOn
|
29 |
Migliorati CA. Bisphosphanates and oral cavity avascular bone necrosis. J Clin Oncol 2003;21:4253-4.
DOI
ScienceOn
|
30 |
Diel IJ, Bergner R, Grotz KA. Adverse effects of bisphosphonates: current issues. J Support Oncol 2007;5:475-82.
|
31 |
Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 2004;62:527-34.
DOI
ScienceOn
|